- Trial phase
- Phase 3 (failed)
- Time to market
- Not applicable. The drug failed all Phase 3 trials and development has been terminated.
- Why 0/10
- No upcoming catalysts exist for ampreloxetine. The drug failed its pivotal Phase 3 CYPRESS study in March 2026, Theravance was acquired by Zymeworks and delisted in September 2026, and the program has been effectively terminated. ImpactScore is 0 because the developer no longer exists as a public company and the drug has no active development path.
Ampreloxetine is a failed drug with no active development program. Theravance Biopharma (TBPH) was acquired by Zymeworks (ZYME) in a deal that closed September 2026, and TBPH shares were delisted. There are no upcoming catalysts for this drug. For investors, the relevant surviving public company is Zymeworks (ZYME), which acquired Theravance primarily for its commercial YUPELRI respiratory asset, not for ampreloxetine.
Price Chart
Executive Summary
Ampreloxetine (TD-9855) was Theravance Biopharma's investigational once-daily norepinephrine reuptake inhibitor for symptomatic neurogenic orthostatic hypotension (nOH). The drug failed three consecutive Phase 3 trials: SEQUOIA (2021), REDWOOD (2022), and the pivotal CYPRESS study in MSA patients (March 2026). The CYPRESS failure triggered a 50% workforce reduction and a strategic review that led to Theravance's acquisition by Zymeworks for $929 million. The acquisition closed in September 2026, TBPH was delisted, and ampreloxetine development has been effectively terminated. There is no publicly traded stock tied to this drug's development anymore.
How It Works
Ampreloxetine is a norepinephrine reuptake inhibitor, meaning it increases levels of the neurotransmitter norepinephrine in the body. This helps raise blood pressure by improving the constriction of blood vessels. It was being studied as a once-daily pill for neurogenic orthostatic hypotension (nOH), a condition where the nervous system fails to regulate blood pressure properly, causing dangerous drops when a person stands up.
Trial Status
Ampreloxetine completed three Phase 3 trials: Study 0169 (SEQUOIA, topline September 2021) and Study 0170 (REDWOOD, topline April 2022) both failed in mixed nOH populations. The third Phase 3 trial, CYPRESS (NCT05696717), specifically in nOH due to multiple system atrophy (MSA), failed its primary endpoint in March 2026. Detailed CYPRESS data were presented in August 2026. No further trials are planned.
The Two-Sided Case
Upcoming Catalysts
- None. The drug program has been terminated and the developer acquired and delisted.
Source Filing
The SecBot filing or press-release report that triggered this drug report:
Theravance Biopharma, Inc. 8-K TBPH ·Originating report